A role for p38 MAPK in head and neck cancer cell growth and tumor-induced angiogenesis and lymphangiogenesis

Molecular Oncology

Volumn 8, Issue 1, 2014, Pages 105-118

  Leelahavanichkul, Kantima ^a,c   Amornphimoltham, Panomwat ^a   Molinolo, Alfredo A ^a   Basile, John R ^b   Koontongkaew, Sittichai ^c   Gutkind, J Silvio ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

^c THAMMASAT UNIVERSITY   (Thailand)

Author keywords

Angiogenesis; Head and neck cancer; JNK; Lymphangiogenesis; MAPK; P38 Inhibitor; P38 MAPK

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE 3; SHORT HAIRPIN RNA; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER TISSUE; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPHANGIOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TISSUE MICROARRAY; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT;

ANGIOGENESIS; HEAD AND NECK CANCER; JNK; LYMPHANGIOGENESIS; MAPK; P38 INHIBITOR; P38 MAPK;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINES; ENZYME ACTIVATION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LYMPHANGIOGENESIS; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; P38 MITOGEN-ACTIVATED PROTEIN KINASES; TUMOR MICROENVIRONMENT;

EID: 84893001423     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.10.003     Document Type: Article

References (38)

1. Agrawal N., Frederick M.J., Pickering C.R., Bettegowda C., Chang K., Li R.J., Fakhry C., Xie T.X., Zhang J., Wang J., Zhang N., El-Naggar A.K., Jasser S.A., Weinstein J.N., Trevino L., Drummond J.A., Muzny D.M., Wu Y., Wood L.D., Hruban R.H., Westra W.H., Koch W.M., Califano J.A., Gibbs R.A., Sidransky D., Vogelstein B., Velculescu V.E., Papadopoulos N., Wheeler D.A., Kinzler K.W., Myers J.N. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011, 333:1154-1157.
2. Albanell J., Codony-Servat J., Rojo F., Del Campo J.M., Sauleda S., Anido J., Raspall G., Giralt J., Rosello J., Nicholson R.I., Mendelsohn J., Baselga J. Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res. 2001, 61:6500-6510.
3. Amornphimoltham P., Leelahavanichkul K., Molinolo A., Patel V., Gutkind J.S. Inhibition of mammalian target of rapamycin by rapamycin causes the regression of carcinogen-induced skin tumor lesions. Clin. Cancer Res. 2008, 14:8094-8101.
4. Amornphimoltham P., Patel V., Leelahavanichkul K., Abraham R.T., Gutkind J.S. A retroinhibition approach reveals a tumor cell-autonomous response to rapamycin in head and neck cancer. Cancer Res. 2008, 68:1144-1153.
5. Chen L., Mayer J.A., Krisko T.I., Speers C.W., Wang T., Hilsenbeck S.G., Brown P.H. Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells. Cancer Res. 2009, 69:8853-8861.
6. Chen Z., Malhotra P.S., Thomas G.R., Ondrey F.G., Duffey D.C., Smith C.W., Enamorado I., Yeh N.T., Kroog G.S., Rudy S., McCullagh L., Mousa S., Quezado M., Herscher L.L., Van Waes C. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin. Cancer Res. 1999, 5:1369-1379.
7. Cuenda A., Rousseau S. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim. Biophys. Acta 2007, 1773:1358-1375.
8. Davidson B., Konstantinovsky S., Kleinberg L., Nguyen M.T., Bassarova A., Kvalheim G., Nesland J.M., Reich R. The mitogen-activated protein kinases (MAPK) p38 and JNK are markers of tumor progression in breast carcinoma. Gynecol. Oncol. 2006, 102:453-461.
9. Davies S.P., Reddy H., Caivano M., Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 2000, 351:95-105.
10. Forastiere A., Koch W., Trotti A., Sidransky D. Head and neck cancer. N. Engl. J. Med. 2001, 345:1890-1900.
11. Gaundar S.S., Bendall L.J. The potential and limitations of p38MAPK as a drug target for the treatment of hematological malignancies. Curr. Drug Targets 2010, 11:823-833.
12. Gaundar S.S., Bradstock K.F., Bendall L.J. p38MAPK inhibitors attenuate cytokine production by bone marrow stromal cells and reduce stroma-mediated proliferation of acute lymphoblastic leukemia cells. Cell Cycle 2009, 8:2975-2983.
13. Gill K., Mohanti B.K., Ashraf M.S., Singh A.K., Dey S. Quantification of p38alphaMAP kinase: a prognostic marker in HNSCC with respect to radiation therapy. Clin. Chim. Acta 2012, 413:219-225.
14. Greenberg A.K., Basu S., Hu J., Yie T.A., Tchou-Wong K.M., Rom W.N., Lee T.C. Selective p38 activation in human non-small cell lung cancer. Am. J. Respir. Cell Mol. Biol. 2002, 26:558-564.
15. Hasina R., Lingen M.W. Angiogenesis in oral cancer. J. Dent. Educ. 2001, 65:1282-1290.
16. Hui L., Bakiri L., Mairhorfer A., Schweifer N., Haslinger C., Kenner L., Komnenovic V., Scheuch H., Beug H., Wagner E.F. p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat. Genet. 2007, 39:741-749.
17. Hui L., Bakiri L., Stepniak E., Wagner E.F. p38alpha: a suppressor of cell proliferation and tumorigenesis. Cell Cycle 2007, 6:2429-2433.
18. Kumar B., Koul S., Petersen J., Khandrika L., Hwa J.S., Meacham R.B., Wilson S., Koul H.K. p38 Mitogen-activated protein kinase-driven MAPKAPK2 regulates invasion of bladder cancer by modulation of MMP-2 and MMP-9 activity. Cancer Res. 2010, 70:832-841.
19. Leelahavanichkul K., Gutkind J.S. Oral and pharyngeal epithelial cell culture. Methods in Molecular Biology 2012, Humana Press. second ed. S.H. Randell (Ed.).
20. Malhotra R., Patel V., Chikkaveeraiah B.V., Munge B.S., Cheong S.C., Zain R.B., Abraham M.T., Dey D.K., Gutkind J.S., Rusling J.F. Ultrasensitive detection of cancer biomarkers in the clinic by use of a nanostructured microfluidic array. Anal. Chem. 2012, 84:6249-6255.
21. Marinissen M.J., Chiariello M., Pallante M., Gutkind J.S. A network of mitogen-activated protein kinases links G protein-coupled receptors to the c-jun promoter: a role for c-Jun NH2-terminal kinase, p38s, and extracellular signal-regulated kinase 5. Mol. Cell Biol. 1999, 19:4289-4301.
22. Molinolo A.A., Hewitt S.M., Amornphimoltham P., Keelawat S., Rangdaeng S., Meneses Garcia A., Raimondi A.R., Jufe R., Itoiz M., Gao Y., Saranath D., Kaleebi G.S., Yoo G.H., Leak L., Myers E.M., Shintani S., Wong D., Massey H.D., Yeudall W.A., Lonardo F., Ensley J., Gutkind J.S. Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin. Cancer Res. 2007, 13:4964-4973.
23. Patel V., Marsh C.A., Dorsam R.T., Mikelis C.M., Masedunskas A., Amornphimoltham P., Nathan C.A., Singh B., Weigert R., Molinolo A.A., Gutkind J.S. Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer. Cancer Res. 2011, 71:7103-7112.
24. Pearson G., Robinson F., Beers Gibson T., Xu B.E., Karandikar M., Berman K., Cobb M.H. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr. Rev. 2001, 22:153-183.
25. Pries R., Wollenberg B. Cytokines in head and neck cancer. Cytokine Growth Factor Rev. 2006, 17:141-146.
26. Rodriguez-Berriguete G., Fraile B., Martinez-Onsurbe P., Olmedilla G., Paniagua R., Royuela M. MAP kinases and prostate cancer. J. Signal Transduct. 2012, 2012:169170.
27. Rusling J.F., Kumar C.V., Gutkind J.S., Patel V. Measurement of biomarker proteins for point-of-care early detection and monitoring of cancer. Analyst 2010, 135:2496-2511.
28. Sanchez-Prieto R., Rojas J.M., Taya Y., Gutkind J.S. A role for the p38 mitogen-activated protein kinase pathway in the transcriptional activation of p53 on genotoxic stress by chemotherapeutic agents. Cancer Res. 2000, 60:2464-2472.
29. Schaeffer H.J., Weber M.J. Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol. Cell Biol. 1999, 19:2435-2444.
30. Siegel R., Desantis C., Virgo K., Stein K., Mariotto A., Smith T., Cooper D., Gansler T., Lerro C., Fedewa S., Lin C., Leach C., Cannady R.S., Cho H., Scoppa S., Hachey M., Kirch R., Jemal A., Ward E. Cancer treatment and survivorship statistics, 2012. CA Cancer J. Clin. 2012, 62:220-241.
31. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 2012, 62:10-29.
32. Specenier P.M., Vermorken J.B. Current concepts for the management of head and neck cancer: chemotherapy. Oral Oncol. 2009, 45:409-415.
33. Stransky N., Egloff A.M., Tward A.D., Kostic A.D., Cibulskis K., Sivachenko A., Kryukov G.V., Lawrence M.S., Sougnez C., McKenna A., Shefler E., Ramos A.H., Stojanov P., Carter S.L., Voet D., Cortes M.L., Auclair D., Berger M.F., Saksena G., Guiducci C., Onofrio R.C., Parkin M., Romkes M., Weissfeld J.L., Seethala R.R., Wang L., Rangel-Escareno C., Fernandez-Lopez J.C., Hidalgo-Miranda A., Melendez-Zajgla J., Winckler W., Ardlie K., Gabriel S.B., Meyerson M., Lander E.S., Getz G., Golub T.R., Garraway L.A., Grandis J.R. The mutational landscape of head and neck squamous cell carcinoma. Science 2011, 333:1157-1160.
34. Thomas B., Stedman M., Davies L. Grade as a prognostic factor in oral squamous cell carcinoma: a population based analysis of the data. Laryngoscope 2013, (Epub ahead of print).
35. Turjanski A.G., Vaque J.P., Gutkind J.S. MAP kinases and the control of nuclear events. Oncogene 2007, 26:3240-3253.
36. Vanderkerken K., Medicherla S., Coulton L., De Raeve H., Willems A., Lawson M., Van Camp B., Protter A.A., Higgins L.S., Menu E., Croucher P.I. Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma. Cancer Res. 2007, 67:4572-4577.
37. Wagner E.F., Nebreda A.R. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat. Rev. Cancer 2009, 9:537-549.
38. Yoshizuka N., Chen R.M., Xu Z., Liao R., Hong L., Hu W.Y., Yu G., Han J., Chen L., Sun P. A novel function of p38-regulated/activated kinase in endothelial cell migration and tumor angiogenesis. Mol. Cell Biol. 2012, 32:606-618.